Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Leukemia, Myeloid, Chronic-Phase 12Leukemia 6Gastrointestinal Stromal Tumors 6Neoplasm Metastasis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Synovitis, Pigmented Villonodular 2Recurrence 2Ovarian Neoplasms 2Hematologic Diseases 2Blast Crisis 2Substance Withdrawal Syndrome 1Peritoneal Neoplasms 1Neoplastic Processes 1Neoplasm, Residual 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Trastuzumab 304Paclitaxel 258Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × nilotinib × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡